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Edited by Jesus AvilaAbstract In vivo and in vitro studies have suggested a neuropro-
tective role for Pituitary adenylate cyclase activating polypep-
tide (PACAP) against neuronal insults. Here, we showed that
PACAP27 protects against neurotoxicity induced by rotenone,
a mitochondrial complex I inhibitor that has been implicated in
the pathogenesis of Parkinsons disease (PD). The neuroprotec-
tive eﬀect of PACAP27 was dose-dependent and blocked by its
speciﬁc receptor antagonist, PACAP6-27. The eﬀects of PA-
CAP27 on rotenone-induced cell death were mimicked by dibuty-
ryl-cAMP (db-cAMP), forskolin and prevented by the PKA
inhibitor H89, the ERK inhibitor PD98059 and the p38 inhibitor
SB203580. PACAP27 administration blocked rotenone-induced
increases in the level of caspase-3-like activity, whereas could
not restore mitochondrial activity damaged by rotenone. Thus,
our results demonstrate that PACAP27 has a neuroprotective
role against rotenone-induced neurotoxicity in neuronal diﬀeren-
tiated PC12 cells and the neuroprotective eﬀects of PACAP are
associated with activation of MAP kinase pathways by PKA and
with inhibition of caspase-3 activity; the signaling mechanism ap-
pears to be mediated through mitochondrial-independent path-
ways.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Parkinsons disease (PD) is a motor disorder characterized
by bradykinesia, akinesia, rigidity and tremors [1,2]. Idiopathic
PD results from the degeneration of dopaminergic neurons in
the substantia nigra. Inhibition of mitochondrial complex I
activity has been implicated in the pathogenesis of PD [3]
and has been used extensively as a model system with whichAbbreviations: db-cAMP, dibutyryl-cAMP; DMEM, Dulbeccos mod-
iﬁed Eagles medium; ERK, extracellular signal-regulated kinase; H89,
N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinolinesulfonamide; JC-1,
5,5 0,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolcarbocyanine io-
dide; MAP, mitogen-activated protein; Myr-WPKC, myristoyl-Gly-
Arg-Arg-Asn-Ala-Ile-His-Asp-Ile; PACAP, pituitary adenylate cyclase
activating polypeptide; PKA, protein kinase A; PKC, protein kinase C;
TPA, 12-O-tetradecanoyl-phorbol-13-acetate
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tion of complex I activity results in ATP inhibition and loss of
mitochondrial membrane potential, leading to the death of ni-
gral neurons [4]. Rotenone, a mitochondrial complex I inhibi-
tor, can recapitulate the behavioral [5] and neuropathological
hallmarks of PD [6,7], including induction of apoptosis and
acceleration of a-synuclein formation in PD models in vivo
[8] and in vitro [9]. Hence, these features of rotenone make it
a useful model of PD both in vivo and in vitro.
Pituitary adenylate cyclase-activating polypeptide (PACAP)
was ﬁrst isolated from hypothalamic extracts on the basis of its
ability to stimulate adenylate cyclase activity in pituitary cells.
PACAP has been designated to the VIP/secretin/glucagon fam-
ily of peptides because of its 68% identity with vasoactive intes-
tinal peptide [10,11]. There are two forms of mammalian
PACAP (27 or 38 amino acid residues) and both have been
shown to have similar biological activity and receptor-binding
activity. PACAP receptors belong to the family of G protein-
coupled receptors with seven transmembrane domains, and
there are at least three types of PACAP receptors: PAC1,
VPAC1 and VPAC2. The PAC1 receptor is mainly localized
in the central nervous system and the anterior pituitary, while
VPAC1 and VPAC2 receptors are concentrated in peripheral
tissues, such as the lung, kidney and liver. The PAC1 receptor
is coupled to adenylate cyclase (AC) and phospholipase C,
through AC activation and it elevates cAMP and activates
protein kinase A (PKA), which can activate the mitogen-
activated protein kinase (MAPK) pathway. However, PACAP
can also activate the MAPK pathway independently of AC
activation [12,13].
Recent studies have indicated that PACAP is a promising
neuroprotective peptide and that it may play an important role
during nervous system development and during regeneration
following nervous system injuries [14]. PACAP has also been
shown to protect against apoptosis induced by neurotoxins
including glutamate [15,16], beta-amyloid [17], 6-hydroxydop-
amine (6-OHDA) [18] and human prion protein [19]. Finally,
in vitro studies have shown that PACAP can stimulate neurite
outgrowth [20].
In the present study, we investigated the eﬀects of PACAP27
on rotenone-induced neurotoxicity using neuron-like PC12
cells in vitro in which the expression of PACAP-speciﬁc
PAC1 receptor was conﬁrmed [17,21]. We investigated the
inﬂuence of PACAP27 on caspase-3 activity (which plays a
crucial role in apoptosis of PC12 cells) and whether PACAP27
could restore mitochondrial integrity after damage by rote-
none. We further investigated whether the protective eﬀectsblished by Elsevier B.V. All rights reserved.
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lar signal-regulated kinase (ERK) and p38 MAPK signaling.2. Materials and methods
2.1. Chemicals
Rotenone, PACAP27, PACAP6-27, MTT, DMSO, dibutyryl-cAMP
(db-cAMP), forskolin, 12-O-tetradecanoyl-phorbol-13-acetate (TPA),
H-89 and myristoyl-Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-Ile (Myr-W)
protein kinase C (PKC) were purchased from Sigma (St. Louis, MO,
USA); PD98059, SP600125 and SB203580 were purchased from Bio-
mol (Plymouth Meeting, PA, USA); Annexin-V and propidium iodide
(PI) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA); Apo-ONEe. Homogeneous Caspase-3/7 Assay kits were pur-
chased from Promega (Madison, WI, USA); JC-1 and Hoechst
33258 were purchased from Molecular Probes (Eugene, OR, USA).
2.2. Cell culture
Rat pheochromocytoma (PC12) cells were obtained from the cell
bank of Institute of Biochemistry and Cell Biology, SIBS, CAS
(Shanghai, China) and cultured in Dulbeccos modiﬁed Eagles med-
ium (DMEM; Sigma) supplemented with 5% (v/v) horse serum (Gibco
BRL, Grand Island, NY, USA) and 5% (v/v) newborn calf serum (Gib-
co BRL), 100 U/ml penicillin, and 100 lg/ml streptomycin in a 75 ml
vented culture ﬂask (Corning, Acton, MA). The cultures were main-
tained in 5% CO2/95% humidiﬁed air at 37 C. Medium was changed
every 2 days. By 3–4 days of incubation in the ﬂask, cells had reached
70–80% conﬂuence and were seeded onto a 10 mm-diameter 96-well
plate at a cell density of 1 · 104/well for test.
2.3. Cell survival
PC12 cells were treated and cultured for 24 h in the absence or pres-
ence of rotenone (50–5000 nM), PACAP27 (1013–106 M), PACAP6-
27 (105 M), db-cAMP (a cAMP analog) (104 M), forskolin
(106 M), TPA (a PKC activator) (107 M), H-89 (a PKA inhibitor)
(106 M), Myr-WPKC (a PKC inhibitor) (106 M), PD98059 (an
ERK inhibitor) (2 · 105 M), SP600125 (a JNK inhibitor)
(5 · 105 M) or SB203580 (a p38 inhibitor) (4 · 105 M). After 24 h
of drug treatment, cells were incubated for 4 h with 5 g/l MTT and
then DMSO (200 ll) was added for 15 min. MTT reduction was quan-
tiﬁed at 570 nm using a micro-plate reader (Bio-Tek Instruments Inc.,
Canada). For quantiﬁcation of surviving cells, free-ﬂoating cells
pooled with cells detached by mild trypsinization were incubated in
100 ll annexin-V-FLUOS buﬀer solution containing 2 ll Annexin-V
and 2 ll PI reagent for 10–15 min at 20 C and then cooled so that
the reaction was terminated. FITC-ﬂuorescence densities were mea-
sured with a FACS Calibur ﬂow cytometer. Flow cytometry used an
excitation wavelength of 488 nm. To detect morphological changes
of PC12 cells after 24 h incubations, cultured cells were visualized on
a ﬂuorescence microscope. For evaluation of morphological changes
to the nuclei (e.g., apoptosis), cells were stained with Hoechst 33258
and visualized by ﬂuorescence microscopy.
2.4. Caspase-3-like activity
Caspase-3-like activity in culture was measured using an Apo-
ONEe Homogeneous Caspase-3/7 Assay Kit (Promega) according
to the manufacturers instructions. Brieﬂy, cells (5 · 104 cells/well) in
type I collagen-coated 96-well plates (Corning) were rinsed twice with
phosphate-buﬀered saline (PBS). The cultures were incubated with or
without the indicated stimulants in DMEM (50 ll) at 37 C in an
atmosphere of 95% air and 5% CO2. Cells were lysed in 50 ll of Homo-
geneous Caspase-3/7 Buﬀer containing the caspase-3 substrate
Z-DEVD-rhodamine 110, and the cell lysates were incubated for 4 h
at room temperature. Fluorescence intensity (excitation at 498 nm
and emission at 521 nm) was measured with an saﬁre2 spectroﬂuoro-
photometer (Tecan Genios Plus, Switzerland).2.5. Measurement of mitochondrial membrane potential
Mitochondrial membrane potential was quantiﬁed using the ratio-
metric probe JC-1 (Molecular Probes). In healthy PC12 cells, the intact
membrane allows the lipophilic dye JC-1 to enter into the mitochon-dria where it accumulates and aggregates, producing an intense orange
signal. In apoptotic cells, where the mitochondrial membrane potential
has collapsed, the monomeric JC-1 remains in the cytosol and appears
green. PC12 cells were treated for 24 h with rotenone (250 nM) in the
absence or presence of PACAP. Cells were incubated for 30 min with
10 lg/ml JC-1 at 37 C under 5% CO2, and then washed twice with
0.1 M PBS. The proportion of aggregated vs. monomeric JC-1 probe
was quantiﬁed using the ratio of ﬂuorescence emissions at 590 nm (or-
ange) over 530 nm (green) with a FACS Calibur ﬂow cytometer.
2.6. Data analysis
Statistical analyses were done by SPSS software using a one-way
ANOVA, followed by a two-tailed Students t-test or multiple compar-
ison test where appropriate. A P < 0.05 was considered signiﬁcant for
all analyses.3. Results
3.1. PAC1 receptors mediate eﬀects of PACAP27 on rotenone-
induced cytotoxicity
Chronic exposure of PC12 cells to rotenone resulted in a con-
centration-dependent decrease of cell viability as assayed by
MTT at 24 h, indicating a reduction in the mitochondria of
living cells (Fig. 1G). Observed morphological changes associ-
ated with increasing rotenone exposure, included cell shrinkage,
disappearance of neurites, nuclear condensation and DNA
fragmentation (Fig. 1A–F). PACAP27 is believed to act as a
potent neurotrophic factor in the nervous system. When co-
treated with rotenone, a signiﬁcant (P < 0.05) increase of MTT
was observed at concentrations of 1012–107 M (Fig. 1H).
However, when PACAP27 was administered to PC12 cells with
PACAP6-27 (105 M), a potent PAC1 receptor antagonist, in
presence of rotenone, its protective eﬀects largely disappeared
(Fig. 1I). Taken together, these results indicate that the eﬀects
of PACAP27 are mediated through the activation of PAC1
receptors in PC12 cells. In fact, extremely low concentrations
exerted marked eﬀects on the biological activity of the cells.
Additionally, because cytotoxicity induced by rotenone is
mainly evidenced by apoptosis rather necrosis, FACS and
Annexin-V-PI double staining were used to detect apoptotic
cells. We found that PACAP not only decreased numbers of
apoptotic cells, but promoted cells to transform from late apop-
tosis to early apoptosis (Fig. 2).
3.2. PKA and ERK/p38 MAPK transduction pathways involved
in neuroprotective eﬀects of PACAP27
To determine which signaling pathways are involved in the
protective eﬀects of PACAP27, we investigated whether the
protective eﬀects of PACAP27 were inﬂuenced by stimulators
or inhibitors of diﬀerent protein kinases. In this series of exper-
iments, we found that db-cAMP (104 M), the cell permeant
cAMP analog and forskolin (106 M), a potent PKA stimula-
tor, markedly inhibited the eﬀects of rotenone-induced cyto-
toxicity, as compared to TPA (107 M), a potent PKC
stimulator (Fig. 3A). Co-administration of the selective PKA
inhibitor N-(2-[p-bromocinnamylamino]ethyl)-5-isoquinoline-
sulfonamide (H89) (106 M) with rotenone (250 nM) and PA-
CAP27 (108 M) inhibited the eﬀect of PACAP27. However,
the selective PKC inhibitor, Myr-WPKC (106 M) had no ef-
fect (Fig. 3B).
Previous studies have revealed that MAPK is involved in
PACAP-evoked neuroprotection against various neuronal in-
sults. However, studies examining which MAPK subtype is
Fig. 1. Rotenone-induced cell death and neuroprotective eﬀects of PACAP27 in PC12 cells. (A)–(D) Photomicrographs of PC12 cells after exposure
to various concentrations of rotenone by ﬂuorescence microscope without any stain and show dose-dependent eﬀects of rotenone. (A) Control cells.
(B) Cells treated with rotenone (50 nM) for 24 h. (C) Cells treated with rotenone (100 nM) for 24 h. (D) Cells treated with rotenone (250 nM) for
24 h. (E) and (F) Photomicrographs of PC12 cells stained with Hoechst 33258 and visualized by ﬂuorescence microscopy. (E) Control cells. (F) Cells
treated with rotenone (250 nM) for 24 h; (A)–(F) note the morphological changes associated with increasing rotenone exposure, including cell
shrinkage, disappearance of neurites, nuclear condensation and DNA fragmentation (ﬂ), Bar = 100 lm. (G) Dose-dependent neurotoxicity of
rotenone from 0 to 5000 nM for 24 h by MTT detection. The data are represented as means ± S.D. of four experiments. ##P < 0.01 vs. Control
group. (H) Neuroprotective eﬀects of PACAP27 against rotenone-induced neurotoxicity of PC12 cells. The data are represented as means ± S.D. of
four experiments. ##P < 0.01 and #P < 0.05 vs. rotenone (250 nM) group (ﬂ). I: PACAP27 protects PC12 cells from rotenone-induced toxicity and
PACAP6-27, an antagonist of PACAP receptor, blocks its protective eﬀects. The data are represented as means ± S.D. of four experiments.
##P < 0.01 vs. control group. **P < 0.01 vs. rotenone (250 nM) group. nnP < 0.01 vs. PACAP27 (108 M)-treated group with rotenone (250 nM).
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posed to ERK, JNK and p38 inhibitors with rotenone and PA-
CAP27 and found that PD98059 (2 · 105 M), SB203580
(5 · 105 M), but not SP600125 (4 · 105 M), markedly inhib-
ited PACAP27-induced neuroprotection (Fig. 3C). These re-
sults demonstrate that the neuroprotective eﬀects of
PACAP27 are mediated through PKA and ERK/p38, but
not PKC or JNK, signaling pathways.3.3. PACAP27 blocks rotenone-induced impairments on
caspase-3-like activity and does not rescue mitochondrial
membrane potential
Because the activation of caspase-3 occurs following various
neuronal insults and under certain pathological conditions, we
examined caspase-3-like activity in PC12 cells by measuring
the ability of cell lysates to cleave a ﬂourometric caspase-3 sub-
strate, Z-DEVD-Rhodamine 110. After 24 h of exposure to
Fig. 2. PACAP27 markedly inhibits rotenone-induced apoptosis in PC12 cells. (A)–(C) Micrographs of PC12 cells with ﬂuorescent images with
Annexin V-PI double-staining. (A) Control cells. (B) Cells treated with rotenone (250 nM) for 24 h. (C) Cells treated with rotenone (250 nM) and
PACAP27 (108 M) for 24 h. Bar = 100 lm. (D)–(G) Micrographs of PC12 cells by ﬂow cytometry. (D) Control. (E) Cells treated with rotenone
(250 nM) for 24 h. (F) Cells treated with rotenone (250 nM) and PACAP27 (108 M). (G) Cells treated with rotenone (250 nM) and PACAP27
(108 M) in the presence of PACAP6-27 (105 M). (H) Apoptotic rate of PC12 cells (%) by ﬂow cytometry FACS. Each value represents the
means ± S.D. of three independent experiments. #P < 0.05, ##P < 0.01 vs. control. *P < 0.05 vs. rotenone (250 nM) group. nP < 0.05 vs. PACAP27
(108 M)-treated group with rotenone (250 nM).
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markedly increased compared to control groups. Exposure of
these cells to PACAP27(108–107 M) reduced the basal level
of caspase-3-like activity and provoked a signiﬁcant (P < 0.05)
reduction of rotenone-evoked caspase-3-like activation. This
eﬀect was reversed by PACAP6-27 (105 M). Thus, the present
results suggest that PACAP27-induced neuroprotection
against rotenone-induced cytotoxicity may be mediated via
caspase-3 deactivation (Fig. 4).
In order to determine whether rotenone-induced apoptosis
of PC12 cells could be ascribed to an alteration of mitochon-
drial activity and the relationship between caspase-3 deactiva-
tion and mitochondrial damage, the membrane potential of
mitochondria was measured using the ratiometric probe JC-
1. Rotenone treatment for 24 h caused a marked decrease of
mitochondrial membrane potential. However, addition of PA-
CAP27 (107–108 M) did not rescue the membrane potential,
nor did it restore mitochondrial activity (Fig. 5). Taken to-
gether, the data indicate that inhibition of caspase-3 activity
by PACAP27 is likely mediated through mitochondrial-
independent pathways.4. Discussion
In this study, we determined that PACAP27 increased cell
survival against the neurotoxic eﬀects of rotenone, a mitochon-
drial toxin implicated in the pathogenesis of PD. We demon-
strated that PACAP protects diﬀerentiated PC12 cells against
rotenone-induced apoptosis and that the neuroprotective eﬀect
of PACAP is associated with: (1) activation of MAPK by
PKA; and (2) inhibition of caspase-3 activity mediated
through a mitochondrial-independent pathway.
The neuroprotective eﬀects of PACAP have been demon-
strated on various neurotoxic agents which induce apoptosis
and/or necrosis, such as glutamate, ethanol, ceramide, beta-
amyloid and 6-OHDA. Our study indicates that the mitochon-
drial complex I inhibitor, rotenone, provoked the death of PC12
cells in a concentration-dependent manner. Rotenone-induced
cell death had the characteristic features of apoptosis including
cell shrinkage, nuclear condensation and DNA fragmentation,
which is consistent with a recent study by Liu et al. [22]. The
neuroprotection of PACAP was eﬀective at extremely low con-
centrations (1012 M), suggesting that PACAP27 could act as a
Fig. 3. Involvement of protein kinase cascades in the neuroprotective
eﬀects of PACAP27. (A) Eﬀects of PKA/PKC activators on rotenone-
induced cell death in PC12 cells. The cells were cultured for 24 h with
rotenone in the presence or absence of db-cAMP (104 M)/forskolin
(106 M) or TPA (107 M). (B) Eﬀects of the selective PKA/PKC
inhibitors on PACAP27-evoked neuroprotection. PC12 cells were
treated with rotenone and PACAP in the absence or presence of the
protein kinase inhibitor (106 M) for 24 h. (C) Eﬀects of selective
MAPK inhibitors on PACAP27-mediated neuroprotection. PC12 cells
were treated with rotenone and PACAP in the absence or presence of
each protein kinase inhibitor for 24 h; cell viability was assessed by
MTT. The data are represented as means ± S.D. of four experiments.
##P < 0.01 and #P < 0.05 vs. the control group. **P < 0.01 and
*P < 0.05 vs. rotenone-treated group. nnP < 0.01 and nP < 0.05 vs.
PACAP27-treated group with rotenone (250 nM).
Fig. 4. Eﬀects of PACAP27 on rotenone-evoked caspase-3 activity.
##P < 0.01 and #P < 0.05 with respect to the control group. **P < 0.01
and *P < 0.05 with respect to rotenone (250 nM)-treated group. Data
are presented as means ± S.D. of three experiments.
Fig. 5. PACAP27 eﬀects on the alteration of mitochondrial membrane
potential induced by rotenone. (A)–(F) Flow cytometry data with
JC-1. (A) Control group. (B) Rotenone(250 nM)-treated group.
(C) PACAP27 (107 M)-treated group with rotenone (250 nM).
(D) PACAP27 (107 M)-treated group with rotenone (250 nM) in
the presence of PACAP6-27 (105 M). (E) PACAP27 (108 M)-treated
group with rotenone (250 nM). (F) PACAP27 (108 M)-treated group
with rotenone (250 nM) in the presence of PACAP6-27 (105 M).
(G) Mitochondrial integrity in PC12 cells. Data are presented as
means ± S.D. of four experiments. ##P < 0.01 and #P < 0.05 vs. the
control group. NS, not statistically diﬀerent vs. rotenone-treated
group.
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eﬀect was attenuated by PACAP6-27, a potent PAC1 receptor
antagonist. Taken together with previous observations that
show that PC12 cells express PACAP-speciﬁc receptor PAC1-
R, these data indicate that the neuroprotective eﬀect of PACAP
against rotenone-induced apoptosis of PC12 cells is mediated
through activation of PAC1-R.
Our results indicate that PC12 cells are sensitive to 24 h expo-
sure to rotenone at 50 nM to 5 lM.This ﬁnding diﬀers frompre-
vious reports [23,24] that 0.03–1 lM of rotenone for 24 h could
not inﬂuence cellular viability. This discrepancy could be due to
the type of PC12 cells used or to diﬀerences in the culture condi-
tions. There are no reported diﬀerences in release, storage or up-
take of catecholamines between neuronal diﬀerentiated PC12
cells and undiﬀerentiated PC12 cells. However, nerve growth
factor (NGF) has been reported to increase electrical excitability
and acetylcholine sensitivity in undiﬀerentiated rat PC12 cells
[25]. The PC12 cells in this study were diﬀerentiated by NGF,
whereas Tai and colleagues used undiﬀerentiated cells. Thus,
our results reveal diﬀerential susceptibility of undiﬀerentiated
versus diﬀerentiated PC12 cells to rotenone-induced neurotox-
icity, with the latter more sensitive to neurotoxins.
The eﬀect of PACAP27 was mimicked by both a cell perme-
ant cAMP analog (db-cAMP) and a potent PKA stimulator
(forskolin). However, a PKC stimulator (TPA) had no eﬀect.
Treatment with a PKA inhibitor (H89), but not a PKC inhib-
itor (Myr-W PKC), attenuated PACAP-evoked neuroprotec-
tion. These results suggest that the neuroprotection of
PACAP against rotenone-induced cell death can be accounted
for by activation of the AC but not phospholipase C/PKC sig-
naling pathway.
In addition to the PKA signaling pathway, MAPK is a key
regulatory enzyme in the ﬁnal common signaling pathway for
PACAP27-induced cellular proliferation, diﬀerentiation and
neuroprotection in PC12 cells, and this kinase is activated by
PKA followed by the activation of adenylate cylase [26,27].
In the MAPK signaling network, the ERK, JNK and p38
MAPK pathways are thought to inﬂuence the fate of PC12
cells [28]. We observed that the protective eﬀect of PACAP
against rotenone-induced cell death was blocked by adminis-
tration of an ERK inhibitor or a selective p38 MAPK inhibi-
tor. However, a JNK inhibitor had no eﬀect. Hence, the
observed PACAP neuroprotection appears to be mediated
via PKA signaling and to involve downstream activation of
ERK and p38 signals.
Apoptosis is a physiologically important cellular suicide
pathway and there is ample evidence indicating apoptosis as
a mechanism of neuronal cell death in PD. Indeed, apoptotic
cells have been observed while examining PD related models
in vivo and in vitro and in brains of PD patients[29]. Apoptosis
is mediated by the family of cysteine, aspartyl-speciﬁc prote-
ases known as caspases, and among these caspases, caspase-3
plays a fundamental role in the apoptosis of PC12 cells. Casp-
ases are activated following various neuronal insults [16,18,30].
In this study, rotenone increased basal caspase-3 activity up to
139% of control levels. After the addition of PACAP27, there
was a signiﬁcant decrease in the catalytic activity of caspase-3,
suggesting that PACAP27 acted as an anti-apoptotic agent
through the deactivation of caspase-3. Caspase-3 can be acti-
vated through mitochondrial-independent or -dependent path-
ways involving inductive caspases such as caspase-8 or
caspase-9, respectively [31].There is little research focused on the relationship between
caspase-3 activity and mitochondrial membrane integrity in
the neuroprotection evoked by PACAP27 in cells. Recently,
one study reported that although PACAP inhibited caspase-3
activity, it did not prevent the deleterious eﬀects of Ab25–35
on mitochondrial potential and granule cell death [30]. Mea-
suring mitochondria activity with the membrane potential-
sensitive probe JC-1 revealed that rotenone strongly decreased
the proportion of active mitochondria. This eﬀect was not af-
fected by PACAP. These results suggest that activation of
caspase-3 by rotenone and inhibition of caspase-3 activity
by PACAP27 could be mediated through a mitochondrial-
independent pathway. Additionally, there may be diﬀerent
relationships between caspase-3 activity and mitochondrial
membrane integrity in non-PC12 cells exposed to neurotoxins.
The degree of involvement of caspase-3 activation in neuro-
toxin-induced apoptosis may be related to cell type and the
speciﬁc neurotoxin employed. Thus, further studies are needed
to fully characterize mechanisms underlying protection against
neurotoxicity.
In conclusion, our results demonstrate for the ﬁrst time that
PACAP27 has a protective role in neuronal diﬀerentiated
PC12 cells against rotenone-induced neurotoxicity. We further
demonstrated that the neuroprotective eﬀects of PACAP
are associated with both activation of MAPK by PKA and
inhibition of caspase-3 activity. The neuroprotective eﬀects
of PACAP appear to be mediated through a mitochondrial-
independent pathway.
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